UCB (UCBJY) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free UCBJY Stock Alerts $67.30 +2.51 (+3.87%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartDividendFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartDividendFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineUCB SA's Dividend Analysisfinance.yahoo.com - April 25 at 10:24 AMUCB (OTCMKTS:UCBJY) Stock Price Passes Above 50-Day Moving Average of $57.90americanbankingnews.com - April 18 at 4:06 AMDrugmakers reportedly planning to raise prices on 500+ drugs in January (update)seekingalpha.com - December 29 at 1:53 PMDrugmakers reportedly planning to raise prices on 500+ drugs in Januarymsn.com - December 29 at 1:53 PMFDA’s new drug approvals for 2023 rise 51% from last yearmsn.com - December 28 at 2:38 PMUCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meetingfinance.yahoo.com - December 1 at 10:15 AMUCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasisfinance.yahoo.com - November 14 at 7:33 AMFDA approves UCB's Bimzelx for plaque psoriasismsn.com - October 18 at 1:49 PMUCB presents late-breaking posters at Child Neurology Society Meetingbenzinga.com - October 4 at 2:03 PMEMA advisors recommend many new meds at latest meetingmsn.com - September 15 at 1:34 PMSkin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Assertsmarkets.businessinsider.com - August 31 at 5:03 PMCrohn's disease drugmakers set to benefit from expected rise in casesmsn.com - August 26 at 5:10 PMUCB (UCBJY) Declares $0.73 Dividendmsn.com - April 13 at 8:32 PMUnited Commercial Bank Ltd.wsj.com - April 6 at 6:23 PMBimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeksbenzinga.com - March 20 at 11:08 PMUCB SA (UCBJY) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - December 23 at 3:12 PMUCB drug meets main goals of 2 phase 3 trials for painful skin disorderseekingalpha.com - December 9 at 5:55 PMUCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022benzinga.com - November 8 at 1:44 PMUCB presents latest data from generalized myasthenia gravis portfolio at AANEM meetingbenzinga.com - September 24 at 6:11 PMUCB SA (UCB.BR)finance.yahoo.com - September 22 at 1:50 PMUCB.BR - UCB SA | Stock Price & Latest News | Reutersreuters.com - September 17 at 10:49 PMUCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congressbenzinga.com - September 2 at 6:04 PMUCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravisfinance.yahoo.com - May 11 at 11:08 PMJAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)markets.businessinsider.com - May 4 at 1:10 AMFINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)markets.businessinsider.com - March 29 at 9:49 PMUCB's Rare Childhood Epilepsy Drug Scores FDA Approvalfinance.yahoo.com - March 28 at 3:44 PMUCB's Fintepla gets FDA approval to treat rare childhood epilepsyseekingalpha.com - March 28 at 7:13 AMUCB completes $1.9B acquisition of Zogenixseekingalpha.com - March 7 at 1:39 PMZogenix Surges After UCB's $1.9B Acquisition Offerca.finance.yahoo.com - January 21 at 8:31 PMUCB says second late-stage psoriatic arthritis trial for bimekizumab met main goalseekingalpha.com - January 21 at 9:53 AMPositive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Studymarkets.businessinsider.com - January 20 at 11:11 PMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Zogenix, Inc. Mergerapnews.com - January 20 at 8:10 AMPositive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trialmarkets.businessinsider.com - December 18 at 12:35 AMUCBJY Real-Time Quotesnasdaq.com - December 18 at 12:35 AMUpdate on U.S. FDA Review of Biologics License Application (BLA) for bimekizumabfinance.yahoo.com - October 16 at 1:22 PMUCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Olderfinance.yahoo.com - August 30 at 7:21 AM Get UCB News Delivered to You Automatically Sign up to receive the latest news and ratings for UCBJY and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). UCBJY Media Mentions By Week UCBJY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UCBJY News Sentiment▼-0.450.41▲Average Medical News Sentiment UCBJY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UCBJY Articles This Week▼30▲UCBJY Articles Average Week Get UCB News Delivered to You Automatically Sign up to receive the latest news and ratings for UCBJY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ARTLW News Today ASCLF News Today AWKNF News Today AXIM News Today BRRGF News Today BCTXW News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:UCBJY) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
